New hope for advanced cancer: first human trial of BHV-1530 begins

NCT ID NCT06874335

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times

Summary

This early-phase study tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site-101
RECRUITING

Irving, Texas, 75039, United States
Site-102
RECRUITING

Fairfax, Virginia, 22031, United States
Site-103
RECRUITING

Austin, Texas, 78758, United States
Site-104
RECRUITING

Houston, Texas, 77030, United States
Site-105
RECRUITING

San Antonio, Texas, 78229, United States
Site-106
RECRUITING

West Valley City, Utah, 84119, United States
Site-107
RECRUITING

Denver, Colorado, 80218, United States
Site-108
RECRUITING

Lake Mary, Florida, 32746, United States
Site-110
RECRUITING

Detroit, Michigan, 48201, United States
Site-112
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Site-115
RECRUITING

Durham, North Carolina, 27710, United States
Site-116
RECRUITING

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR